CN111297866A - Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof - Google Patents
Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof Download PDFInfo
- Publication number
- CN111297866A CN111297866A CN202010156766.4A CN202010156766A CN111297866A CN 111297866 A CN111297866 A CN 111297866A CN 202010156766 A CN202010156766 A CN 202010156766A CN 111297866 A CN111297866 A CN 111297866A
- Authority
- CN
- China
- Prior art keywords
- jak1
- jak3
- methotrexate
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract description 51
- 229960000485 methotrexate Drugs 0.000 title claims abstract description 51
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title claims abstract description 40
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 title claims abstract description 40
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 title claims abstract description 40
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title claims abstract description 40
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 title claims abstract description 40
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 title claims abstract description 39
- 239000003112 inhibitor Substances 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 21
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- -1 1-isobutyl Chemical group 0.000 description 7
- 102000042838 JAK family Human genes 0.000 description 7
- 108091082332 JAK family Proteins 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000014128 RANK Ligand Human genes 0.000 description 5
- 108010025832 RANK Ligand Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000544 articulatio talocruralis Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002997 osteoclast Anatomy 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000000887 Transcription factor STAT Human genes 0.000 description 3
- 108050007918 Transcription factor STAT Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000729176 Fagopyrum dibotrys Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 1
- 101000588067 Homo sapiens Metaxin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101150103227 IFN gene Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100031603 Metaxin-1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 101000727837 Rattus norvegicus Reduced folate transporter Proteins 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 102000027412 enzyme-linked receptors Human genes 0.000 description 1
- 108091008592 enzyme-linked receptors Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940127284 new molecular entity Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 102000027425 tyrosine-kinase associated receptors Human genes 0.000 description 1
- 108091008595 tyrosine-kinase associated receptors Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition containing a JAK3/JAK1/TBK1 inhibitor and methotrexate or pharmaceutically acceptable salts thereof and application thereof, and particularly relates to application of the JAK3/JAK1/TBK1 inhibitor and methotrexate in treatment of autoimmune diseases, particularly rheumatoid arthritis. The combined medication scheme provided by the invention increases the curative effect through the synergistic effect among the medicines, thereby reducing the dosage of a single medicine, reducing the toxicity, reducing the medicine tolerance of a patient and reducing possible adverse reactions, and is expected to provide a new and better medication selection for autoimmune diseases including RA.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition containing a JAK3/JAK1/TBK1 inhibitor and methotrexate, and application and a using method thereof in treatment of autoimmune diseases, particularly rheumatoid arthritis.
Background
The autoimmune disease refers to a disease caused by the damage of self tissues due to the immune reaction of the body to self antigens, and common autoimmune diseases comprise rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukemia, lymphoma and the like.
Rheumatoid Arthritis (RA) is a chronic, autoimmune disease characterized by polyarticular, symmetrical, aggressive synovial inflammation of the joints and possible involvement of extra-articular organs. The etiology of the disease is unknown, the peak age of the disease is between 30 and 50 years old, common women are more than men, and the total morbidity in China is 0.32 to 0.36 percent.
The data indicate that, if not promptly treated, bone destruction occurs in about 75% of patients within 2 years of disease, resulting in joint stiffness, deformity, and severely impaired function, which may lead to loss of labor or even disability. This will lead to a reduction in the patient's living standard, a reduction in the expected life span, and a huge economic burden on the patient himself, the family and the society.
Methotrexate (MTX) has the following structure, with its chemical name: s- (+) -N-2- [4- [ [ (2, 4-diamino-6 pteridinyl) methyl ] methylamino ] benzoyl ] glutamic acid.
MTX is a classic disease-modifying anti-rheumatic drug (DMARD) for the treatment of RA, recommended by various world college of rheumatology guidelines as the first choice for early RA. As a folate reductase inhibitor, MTX exerts the effects of alleviating disease symptoms and slowing the progression of joint damage by inhibiting the synthesis of thymine to reduce chemotaxis of neutrophils and inhibit the release of inflammatory cytokines. Safety of long-term use of drugs requires special attention, since RA cannot be cured yet. Clinical studies have confirmed that the toxic and side effects of long-term use of MTX are mainly gastrointestinal reactions, bone marrow suppression, liver injury, kidney injury, and the like.
The JAKs (janus kinases) are a small family of the intracytoplasmic non-receptor tyrosine protein kinase superfamily, including four known members of JAK1, JAK2, JAK3 and TYK 2. The JAKs function by interacting with tyrosine kinase-associated receptors and transcription factor signal transducers and transcriptional activators (STATs): tyrosine kinase related receptors on cell membranes have no kinase activity per se, but the intracellular segments have binding sites for JAKs, and after the receptors are combined with ligands, tyrosine residues of various target proteins are phosphorylated through activation of the JAKs combined with the receptors so as to realize signal transmission from the extracellular part to the intracellular part; after the JAKs are activated, tyrosine residues on a catalytic receptor are subjected to phosphorylation modification, then the phosphorylation modification and the surrounding amino acid sequences form a 'docking site', STAT proteins are recruited to the 'docking site', finally, the JAKs catalyze the STAT proteins to be subjected to phosphorylation modification, and the activated STAT proteins enter a cell nucleus in a dimer form to be combined with target genes so as to regulate the transcription of the genes.
JAK3 is specifically expressed in hematopoietic cells and modulates cell signaling by binding to the gamma-co-chain (γ c) of cytokine receptor complexes such as IL-2, IL-4, IL-7, IL-9, IL-15, IL-21, JAK1 binds to IL-10, IL-19, IL-20, IL-22, IL-26, IL-28, IFN- α, IFN- γ, IL-6 in the gp130 family, and other receptors containing γ c, among the JAKs family, JAK1 and JAK3 are thought to be more involved in immune modulation, and their aberrant activation plays a key role in the etiology and pathogenesis of various autoimmune diseases (including but not limited to lymphoma, arthritis, psoriasis, Crohn's disease, lupus erythematosus, etc.), and therefore, the development of inhibitors of JAK1 and JAK3 has become a hotspot in the therapeutic field of RA, among others.
TBK1(TANK binding kinase 1) is serine/threonine kinase, which activates its substrates IRF3 and IRF7 transcription factors by direct phosphorylation of specific sites, induces them to be positioned to cell nucleus to promote the transcription of type I IFN gene, and excessive type I IFN expression may cause body damage. In addition, RANKL/nfkb is considered to be one of the most important signaling pathways for osteoclast differentiation, and an increase in soluble RANKL level in synovial fluid of RA patients leads to abnormal activation of nfkb, which leads to an increase in the number of activated osteoclasts, bone resorption, and bone destruction risk. It has been shown that activation of NF κ B is enhanced by kinase activity of TBK1, while RANKL-induced osteoclast differentiation is inhibited by inhibition of TBK1 activity.
The compound shown in the formula (I) is a new molecular entity drug which is exclusively discovered by Shenzhen micro-core biotechnology limited company, and has a novel mechanism. Researches of patents (CN105399685A) and literatures (Shan S., et al.2019, Intimmunopharmacol.77: 105914) show that the compound shown as the formula (I) is a JAK3/JAK1/TBK1 selective inhibitor, and the activation of STATs and IRF3 is reduced through the inhibition of targets, so that CD4 is inhibited+Activation of T cells, function of helper T cells 17, expression of type I Interferon (IFN), and osteoclast differentiation induced by receptor activator of nuclear factor kappa B ligand (RANKL), achieving the therapeutic effect of alleviating RA.
Taken together, MTX and JAK3/JAK1/TBK1 inhibitors are differentiated in the mechanism of alleviating RA. At present, the research of jointly applying the two medicines to the treatment of RA and other autoimmune diseases is not available, the invention combines the two medicines with different mechanisms, and the invention unexpectedly finds that the two medicines have obvious synergistic curative effect on RA, and can provide new and better medication options for reducing single medicine dosage, reducing medicine tolerance of patients and reducing possible adverse reactions.
Disclosure of Invention
The inventor unexpectedly discovers through research that: the MTX or the pharmaceutically acceptable salt thereof is combined with JAK3/JAK1/TBK1 inhibitors, and the compound has synergistic curative effect on RA and other autoimmune diseases.
Therefore, the first aspect of the invention provides a pharmaceutical composition containing MTX or a pharmaceutically acceptable salt thereof and JAK3/JAK1/TBK1 inhibitor, which can effectively relieve symptoms of autoimmune diseases including RA and has a treatment effect remarkably superior to that of any single component.
Inhibitors of JAK3/JAK1/TBK1 for use in the present invention include the compounds described in CN105399685A, the entire contents of which are incorporated herein by reference.
Specifically, the compound in CN105399685A comprises a compound shown as a formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof,
wherein,
R1is halogen or C1-C6 alkyl;
R2is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylcarbonyl, and C1-C6 alkylamino;
R3is hydrogen or halogen;
R4is hydrogen or C1-C4 alkyl;
x is NH, O or S;
y is CO or S (O)2;
Z is a covalent bond, CH2Or (CH)2)2;
n is an integer of 1 to 4;
ring A is a benzene ring, a pyridine ring or a piperidine ring.
More preferably, the JAK3/JAK1/TBK1 inhibitor is N- (3- (5-chloro-2- (4-fluoro-3- (N-methacrylamido) phenylamino) pyrimidinyl-4-amino) propyl) -4-cyanobenzamide having the formula (II):
a pharmaceutical composition according to the invention comprising a JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof.
The weight ratio of the MTX or pharmaceutically acceptable salt thereof (as MTX) to the JAK3/JAK1/TBK1 inhibitor is 1: 100-1: 500.
the effective dose of the MTX or the pharmaceutical salt thereof (calculated by MTX) is 0.1 mg/kg-0.5 mg/kg.
The effective dose of the JAK3/JAK1/TBK1 inhibitor is 20-100 mg/kg; preferably 15-90 mg/kg; most preferably 20 to 80 mg/kg.
According to the pharmaceutical composition of the invention, the JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof may be administered separately, simultaneously or sequentially.
According to the invention, wherein halogen means fluorine, chlorine, bromine, iodine; preferably fluorine, chlorine, bromine; most preferred is chlorine.
The alkyl refers to a saturated branched or branched hydrocarbon group; in particular, C1-C4 alkyl specifically means methyl, ethyl, propyl, isopropyl, butyl, 1-isobutyl, 2-isobutyl, tert-butyl; the C1-C6 alkyl group includes a 5-carbon alkyl group and a 6-carbon alkyl group in addition to the aforementioned C1-C4 alkyl group, and specific examples thereof are not described herein again. The alkyl groups in the compounds of the present invention may be optionally substituted or unsubstituted, and the substituents may include alkyl, halogen, alkoxy, hydrocarbyl, hydroxy, and the like.
The "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" of the present invention refers to an acid addition salt prepared by reacting a compound represented by the formula (I) or MTX with a pharmaceutically acceptable acid, or a salt formed by reacting a compound having an acid group with a pharmaceutically acceptable base. Wherein, the pharmaceutically acceptable acid is preferably selected from inorganic acids (such as hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid, etc.), and organic acids (such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid or benzoic acid, etc.); the pharmaceutically acceptable base is preferably selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium bicarbonate, ammonia water or ammonium bicarbonate, etc.
The stereoisomers include conformational isomers, enantiomers and diastereomers.
The pharmaceutical composition of the invention may further comprise pharmaceutically acceptable excipients.
The pharmaceutical composition according to the present invention can be prepared into various types of administration unit dosage forms, such as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injections (solutions and suspensions), and the like.
For shaping the pharmaceutical composition in tablet form, any excipient known and widely used in the art may be used. For example, carriers such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, and the like; binders such as water, ethanol, propanol, common syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose and potassium phosphate, polyvinylpyrrolidone, etc.; disintegrators such as dry starch, sodium alginate, agar powder and kelp powder, sodium bicarbonate, calcium carbonate, fatty acid esters of polyethylene sorbitan, sodium lauryl sulfate, monoglyceride stearate, starch, lactose and the like; disintegration inhibitors such as white sugar, glycerin tristearate, coconut oil, hydrogenated oil and the like; adsorption promoters such as quaternary ammonium bases and sodium lauryl sulfate, etc.; humectants such as glycerin, starch, and the like; adsorbents such as starch, lactose, kaolin, bentonite, colloidal silicic acid, and the like; and lubricants such as pure talc, stearates, boric acid powder, polyethylene glycol, and the like. If desired, the tablets may also be provided as sugar-coated tablets, enteric-coated tablets, film-coated tablets (e.g., gelatin-coated tablets), bilayer-coated tablets, and multilayer tablets using conventional coating materials.
For shaping the pharmaceutical composition in the form of a pill, any of the excipients known and widely used in the art may be used, for example, carriers such as lactose, starch, coconut oil, hardened vegetable oil, kaolin, talc and the like; binders such as gum arabic powder, tragacanth powder, gelatin, ethanol and the like; disintegrating agents, such as agar and kelp powder.
For the preparation of pharmaceutical compositions in the form of injection solutions, the solutions and suspensions may be sterilized and, preferably, suitable amounts of sodium chloride, glucose or glycerol, etc., may be added to prepare an injection solution which is isotonic with blood. In the preparation of injection, any carrier commonly used in the art may also be used. For example, water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and fatty acid esters of polyethylene sorbitan, and the like. In addition, conventional lytic agents, buffers, analgesics, and the like may be added.
The content of the JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is not particularly limited and can be selected within a wide range, and generally can be 1 to 45% by mass alone, preferably 1 to 30% by mass.
Further, the present invention provides a kit comprising the above pharmaceutical composition.
In the kit of the present invention, the MTX and JAK3/JAK1/TBK1 inhibitors are unit preparations having the same or different specifications, and the preparation is not particularly limited and may be any preparation, and the dosage form described in the above-mentioned present invention is particularly preferable.
According to the present invention, the MTX and JAK3/JAK1/TBK1 inhibitors are preferably provided separately in separate containers.
The weight ratio of the MTX to the JAK3/JAK1/TBK1 inhibitor is 1: 100-1: 500.
wherein the MTX is administered simultaneously, separately or sequentially with a JAK3/JAK1/TBK1 inhibitor.
The invention also provides application of the pharmaceutical composition in preparing a medicament for treating autoimmune diseases.
The autoimmune diseases include rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukemia, lymphoma diseases, etc.
Finally, the present invention provides a method of treating an autoimmune disease comprising the step of administering to a patient in need thereof a therapeutically effective amount of the above pharmaceutical composition or kit.
The pharmaceutical compositions and kits of the present invention may be prepared by methods conventional in the art.
The autoimmune diseases include rheumatoid arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, type I diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukemia, lymphoma diseases, etc.
Advantageous effects
The invention relates to a pharmaceutical composition containing a JAK3/JAK1/TBK1 inhibitor and methotrexate, which has a synergistic effect on autoimmune diseases including RA.
The invention also relates to kits comprising the pharmaceutical compositions such that the JAK3/JAK1/TBK1 inhibitor and methotrexate may be administered separately or simultaneously.
The pharmaceutical composition or the kit according to the invention can reduce the dosage of a single drug, thereby reducing toxicity, reducing drug tolerance of patients and reducing possible adverse reactions, and provides a new and better drug choice for autoimmune diseases.
Drawings
FIG. 1 shows the efficacy of MTX and JAK3/JAK1/TBK1 inhibitors in a rat model of CIA.
FIG. 2H & E staining and microscopic observation of sections of the knee joint (FIG. 2A) and ankle joint (FIG. 2B) of CIA rats after the end of dosing.
Detailed Description
The invention discloses a combination of MTX or pharmaceutically acceptable salts thereof and JAK3/JAK1/TBK1 inhibitors and application thereof in treating autoimmune diseases including RA, and a person skilled in the art can use the contents to realize the combination by appropriately improving process parameters. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the scope of the invention. While the present invention has been described in terms of preferred embodiments of the uses and pharmaceutical compositions described herein, it will be apparent to those skilled in the art that variations and modifications can be made in the uses and pharmaceutical compositions described herein, or in the practice or use of the techniques described herein, as appropriate, without departing from the spirit and scope of the invention.
Experimental part
Experimental materials:
three month old male Sprague Dawley (SD) rats were purchased from the center of medical laboratory animals, Guangdong province.
Bovine type II collagen and incomplete Freund's adjuvant were purchased from Chondrex corporation.
The JAK3/JAK1/TBK1 inhibitor (N- (3- (5-chloro-2- (4-fluoro-3- (N-methylacrylamido) phenylamino) pyrimidinyl-4-amino) propyl) -4-cyanobenzamide, code number CS12192) was synthesized by Shenzhen Microcore Biotech GmbH; methotrexate is purchased from Shanghai-derived leaf Biotech, Inc.
Tissue fixative and EDTA decalcification solutions were purchased from Salarbio. Hematoxylin and eosin staining solutions were purchased from jin Qiao biotechnology, Inc. of Zhongshan, Beijing.
The experimental method comprises the following steps:
bovine type II collagen is added into an equal volume of incomplete Freund's adjuvant for emulsification, a Collagen Induced Arthritis (CIA) model of SD rats is established by tail root injection, 0.2mL is injected into each rat on the first immunization day (marked as day 0), and 0.1mL is injected into each rat on the second immunization day (day 7). Generally, swelling starts to occur on day 10, the peak of the disease occurs on days 13-14, and swelling starts to decline and joint deformation starts on day 21.
The test animals were numbered and divided into 5 groups of 8 animals each, including a normal control group, a model group, an MTX group, a CS12192 group, and an MTX + CS12192 group. Gavage administration was started on the day of the second immunization, wherein the MTX group was administered once per kg body weight per day at 0.2mg MTX; CS12192 group administered 40mg of CS12192 per kg of body weight 2 times a day; the MTX + CS12192 group was administered 0.2mg MTX1 times per kg body weight per day and 40mg CS12192 times per kg body weight 2 times per day.
Scoring was started on the day of the second immunization, using a 16 point scale: four limbs before and after, 4 points per limb: severe swelling of joints or joint deformity divided by 4; the severe red swelling of the joint is 3 points; the moderate red swelling of the joint is 2 points; red spots or slight swelling of the joints were scored as 1; the grade of the powder was 0.
After the administration and scoring, the front and rear paws of each animal were collected, fixed in a tissue fixing solution for 24 hours, decalcified for 3 days, embedded in paraffin and sectioned, and the tissues were cut into 5 μm thick pieces. And (4) carrying out H & E staining after the section is dewaxed, and observing pathological changes of knee joint and ankle joint tissues of each tested animal under a microscope, wherein the pathological changes comprise whether synovial tissues are proliferated, whether inflammatory cells are infiltrated and whether granulation tissues are formed.
The experimental results are as follows:
at the end of 19 days after the start of the experiment, as shown in fig. 1A, the average inflammation score of the model group animals at the end of the experiment was 8.6, which is significantly different from that of the blank control group (P ═ 0.00014), indicating that the CIA pathological model was successfully constructed. By the end of the experiment, the mean inflammation scores of the two monotherapies MTX and CS12192 were 4.14 and 4, respectively, and the P values were 0.027 and 0.018, respectively, compared to the model group, with statistical differences, indicating that both monotherapies at the above doses have a certain therapeutic effect in CIA rats. MTX + CS12192 is a combined medicine group, the average inflammation score at the end of the experiment is 1.86, and compared with a model group, the P value is 0.00010, which shows that the combined medicine has significant statistical significance on the improvement of the CIA disease condition; the combined drug group still has statistical or significant statistical differences compared with the two single drug groups MTX and CS12192 (P values of 0.020 and 0.0093, respectively). FIG. 1B shows the body weight changes of animals recorded in the experiment, and the average body weight of the model group at the end of the experiment is significantly lower than that of the blank control group due to the disease development, and the average body weight increase of each administration group is improved compared with that of the model group.
FIG. 2 shows that after the administration, the knee joints and ankle joints of each group of animals were collected, fixed, sectioned and H & E stained, and then pathological changes were observed under a microscope. In fig. 2A, the knee joint and in fig. 2B, the ankle joint were observed as distinct disease changes in the model group relative to the placebo group: abnormal synovial tissue proliferation, massive inflammatory cell infiltration and granulation tissue formation; in the single medicine group of CS12192 or MTX, the improvement of the disease condition by the medicine can be observed, but a certain amount of abnormal hyperplasia of synovial tissue or inflammatory cell infiltration can be still found; in the combined medicine group of CS12192+ MTX, no pathological features of arthritis were found.
In conclusion, the combination of MTX and JAK3/JAK1/TBK1 inhibitor can obtain a remarkable synergistic curative effect superior to that of a single drug in a collagen-induced arthritis rat model, has no obvious toxic or side effect in the animal model, and is acceptable in safety.
The combinations provided by the present invention and including MTX and JAK3/JAK1/TBK1 inhibitors and uses thereof are described in detail above, and the principles and embodiments of the present invention are described herein using specific examples, which are included to help understand the methods of the present invention and their core concepts, including the best mode, and also to enable any person skilled in the art to practice the invention, including making and using any devices or systems and performing any incorporated methods. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention. The scope of the invention is defined by the claims and may include other embodiments that occur to those skilled in the art. Such other embodiments are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal languages of the claims.
Claims (10)
1. A pharmaceutical composition comprising a JAK3/JAK1/TBK1 inhibitor and Methotrexate (MTX) or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition of claim 1, wherein the JAK3/JAK1/TBK1 inhibitor is a compound of formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof:
wherein,
R1is halogen or C1-C6 alkyl;
R2is one or more substituents selected from the group consisting of hydrogen, hydroxy, cyano, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylcarbonyl, and C1-C6 alkylamino;
R3is hydrogen or halogen;
R4is hydrogen or C1-C4 alkyl;
x is NH, O or S;
y is CO or S (O)2;
Z is a covalent bond, CH2Or (CH)2)2;
n is an integer of 1 to 4;
ring A is a benzene ring, a pyridine ring or a piperidine ring.
4. the pharmaceutical composition of any one of claims 1-4, wherein the JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof are present in admixture in the pharmaceutical composition or are both contained in different parts of the composition, such that the JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof may be used simultaneously or separately.
5. A kit comprising a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1 to 4.
6. The kit of claim 5, wherein the JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof are each a unit formulation of the same or different specifications.
7. The kit of any one of claims 5 to 6, wherein the JAK3/JAK1/TBK1 inhibitor and methotrexate or a pharmaceutically acceptable salt thereof are provided separately in separate containers.
8. The kit according to any one of claims 5 to 7, wherein the amounts of methotrexate or a pharmaceutically acceptable salt thereof and the JAK3/JAK1/TBK1 inhibitor provided in the kit are determined in accordance with 50mg/kg of JAK3/JAK1/TBK1 inhibitor and 0.1mg/kg to 0.5mg/kg of methotrexate or a pharmaceutically acceptable salt thereof, as MTX.
9. Use of a pharmaceutical composition according to any one of claims 1-4 or a kit according to any one of claims 5-8 in the manufacture of a medicament for the treatment of an autoimmune disease.
10. Use according to claim 9, wherein the autoimmune disease comprises rheumatoid arthritis, psoriasis, crohn's disease, systemic lupus erythematosus, multiple sclerosis, type i diabetes, allergic diseases, chronic obstructive pulmonary disease, asthma, leukemia, lymphoma diseases.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010156766.4A CN111297866B (en) | 2020-03-09 | 2020-03-09 | Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof |
TW110107081A TW202143967A (en) | 2020-03-09 | 2021-02-26 | Pharmaceutical composition comprising jak3/jak1/tbk1 inhibitor and methotrexate and use thereof |
PCT/CN2021/078693 WO2021179959A1 (en) | 2020-03-09 | 2021-03-02 | Pharmaceutical composition comprising jak3/jak1/tbk1 inhibitor and methotrexate and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010156766.4A CN111297866B (en) | 2020-03-09 | 2020-03-09 | Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111297866A true CN111297866A (en) | 2020-06-19 |
CN111297866B CN111297866B (en) | 2021-04-02 |
Family
ID=71160495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010156766.4A Active CN111297866B (en) | 2020-03-09 | 2020-03-09 | Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN111297866B (en) |
TW (1) | TW202143967A (en) |
WO (1) | WO2021179959A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112675177A (en) * | 2020-12-28 | 2021-04-20 | 南方医科大学珠江医院 | Pharmaceutical composition containing inhibitor and methotrexate and preparation method and application thereof |
WO2021179959A1 (en) * | 2020-03-09 | 2021-09-16 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition comprising jak3/jak1/tbk1 inhibitor and methotrexate and use thereof |
WO2022222948A1 (en) * | 2021-04-22 | 2022-10-27 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105399685A (en) * | 2014-09-16 | 2016-03-16 | 深圳微芯生物科技有限责任公司 | Preparation method and applications of aromatic heterocyclic compound adopted as selective JAK3 and/or JAK1 kinase inhibitor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105399686B (en) * | 2014-09-16 | 2018-05-22 | 深圳微芯生物科技有限责任公司 | Pyrimidine derivatives, its preparation method and its application |
CN105481778B (en) * | 2014-09-16 | 2019-06-04 | 深圳微芯生物科技股份有限公司 | Pyrimidine derivatives, preparation method and its application |
CN111297866B (en) * | 2020-03-09 | 2021-04-02 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof |
CN112675177A (en) * | 2020-12-28 | 2021-04-20 | 南方医科大学珠江医院 | Pharmaceutical composition containing inhibitor and methotrexate and preparation method and application thereof |
-
2020
- 2020-03-09 CN CN202010156766.4A patent/CN111297866B/en active Active
-
2021
- 2021-02-26 TW TW110107081A patent/TW202143967A/en unknown
- 2021-03-02 WO PCT/CN2021/078693 patent/WO2021179959A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105399685A (en) * | 2014-09-16 | 2016-03-16 | 深圳微芯生物科技有限责任公司 | Preparation method and applications of aromatic heterocyclic compound adopted as selective JAK3 and/or JAK1 kinase inhibitor |
Non-Patent Citations (2)
Title |
---|
ELISA GREMESE等: "JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy", 《J LEUKOC BIOL.》 * |
SONG SHAN等: "Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor,CS12192, in rat and mouse models of rheumatoid arthritis", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021179959A1 (en) * | 2020-03-09 | 2021-09-16 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition comprising jak3/jak1/tbk1 inhibitor and methotrexate and use thereof |
CN112675177A (en) * | 2020-12-28 | 2021-04-20 | 南方医科大学珠江医院 | Pharmaceutical composition containing inhibitor and methotrexate and preparation method and application thereof |
WO2022222948A1 (en) * | 2021-04-22 | 2022-10-27 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
CN117136059A (en) * | 2021-04-22 | 2023-11-28 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing JAK3/JAK1/TBK1 selective inhibitor and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111297866B (en) | 2021-04-02 |
WO2021179959A1 (en) | 2021-09-16 |
TW202143967A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111297866B (en) | Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof | |
EP1772145B1 (en) | Method of effectively using medicine and method concerning prevention of side effect | |
US20060264404A1 (en) | Therapeutic phosphonate compounds | |
EP3019166B1 (en) | A pharmaceutical combination for the treatment of melanoma | |
KR102197429B1 (en) | Pharmaceutical composition and method for the treatment of cardiovascular disease | |
EP3458448B1 (en) | Fasn inhibitors for use in treating non-alcoholic steatohepatitis | |
WO1988004928A1 (en) | Method of inhibiting interleukin-1 activity | |
JPS6341478A (en) | 6-thoxanthine | |
CN105793245A (en) | Pharmaceutical compounds | |
US3705946A (en) | Method of treating hyperuricemia | |
US20150342942A1 (en) | Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone | |
EP0266559B1 (en) | Therapeutic agent for the treatment of peptic ulcer disease | |
EP2117552B1 (en) | Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases | |
Sorbera et al. | CP-690550 | |
EP0000950A1 (en) | Imidazole derivatives and salts thereof and their synthesis | |
JP4235000B2 (en) | Treatment for glomerular diseases | |
JPH07196509A (en) | Pharmaceutical composition containing isoquinoline derivative | |
JPH04178328A (en) | Vascularization-inhibitory agent | |
JPH07324035A (en) | Agent for suppressing proliferation of synoviocyte and agent for treatment of rheumatoid arthritis | |
JPS6337767B2 (en) | ||
JPH0474121A (en) | Agent for inhibiting production of interleukin 1 | |
US20230149387A1 (en) | Treatments | |
KR20230142468A (en) | Administration of fedratinib | |
JPH0120128B2 (en) | ||
AU619732C (en) | Method of inhibiting interleukin-1 activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220623 Address after: No. 18, Xintong South 1st Road, high tech Zone, Chengdu, Sichuan 610000 Patentee after: Chengdu Weixin Pharmaceutical Co.,Ltd. Address before: 518057 room 601-606, building 2, Shenzhen biological incubator, ten Nanshan District high tech Middle Road, Shenzhen, Guangdong, China Patentee before: SHENZHEN CHIPSCREEN BIOSCIENCES Co.,Ltd. Patentee before: Chengdu Weixin Pharmaceutical Co. Ltd. |